JADELLE

This brand name is authorized in Ecuador, Finland, Mexico, Nigeria, New Zealand, South Africa

Active ingredients

The drug JADELLE contains one active pharmaceutical ingredient (API):

1 Levonorgestrel UNII 5W7SIA7YZW - LEVONORGESTREL

The precise mode of action of levonorgestrel as an emergency contraceptive is not known. At the recommended regimen, levonorgestrel is thought to work mainly by preventing ovulation and fertilisation if intercourse has taken place in the preovulatory phase, when the likelihood of fertilisation is the highest. Read about Levonorgestrel

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
JADELLE Implant	Medicines and Medical Devices Safety Authority (NZ)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
G03AC03	Levonorgestrel	G Genito urinary system and sex hormones → G03 Sex hormones and modulators of the genital system → G03A Hormonal contraceptives for systemic use → G03AC Progestogens
Discover more medicines within G03AC03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): 360590612
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 011521, 445346
Country: MX	Comisión Federal para la Protección contra Riesgos Sanitarios	Identifier(s): 044M2011
Country: NG	Registered Drug Product Database	Identifier(s): 04-3559
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 11260
Country: ZA	Health Products Regulatory Authority	Identifier(s): A40/18.1/0138